CytoDyn to Hold Webcast to Provide a Quarterly Company Update
CytoDyn (OTCQB: CYDY) announced that key executives, including Board Chair Tanya Urbach and CFO Antonio Migliarese, will host a webcast on June 30, 2022, to update the investment community. The presentation will provide a quarterly update regarding the company’s progress and developments, focusing on leronlimab, a CCR5 antagonist under development for multiple therapeutic uses. Participants can submit questions ahead of the event and access the replay afterward until July 30, 2022.
- Webcast scheduled for June 30, 2022, indicates transparency and engagement with investors.
- Potential updates on leronlimab, which could lead to positive developments in therapeutic applications.
- No specific financial metrics or performance data provided, leaving investors without concrete information.
- The lack of recent clinical trial results may raise concerns about development progress.
VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Antonio Migliarese, Chief Financial Officer and Interim President, Scott Kelly, Chief Medical Officer and Head of Business Development, and Christopher Recknor, M.D., Senior Director of Research & Development, will host an investment community webcast to provide a quarterly Company update on Thursday, June 30, 2022.
Following the update, questions submitted prior to the webcast as directed below will be addressed to the extent appropriate.
| Date: | Thursday, June 30, 2022 |
| Time: | 1:00 pm PT / 4:00 pm ET |
| Access: | https://event.choruscall.com/mediaframe/webcast.html?webcastid=3aO9FH10 |
| Questions: | Prior to the webcast, questions can be submitted online to ir@cytodyn.com |
This is a livestream presentation. Participants are encouraged to login early prior to the start of the event. The replay will be available approximately 60 minutes after the conclusion of the webcast and can be accessed via the above link until July 30, 2022.
CONTACTS
Investors:
Cristina De Leon
Office: 360.980.8524
ir@cytodyn.com
Media:
Dan Zacchei / Joe Germani
Sloane & Company
dzacchei@sloanepr.com / jgermani@sloanepr.com
FAQ
When is the CytoDyn investor webcast scheduled for?
How can I participate in the CytoDyn webcast?
What will be discussed during the CytoDyn investment community update?
How can I submit questions for the CytoDyn webcast?
Will a replay of the CytoDyn webcast be available?
